Clinical Trials
12 trialsNCT00238355 2025-04-27
Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01503515 2024-10-16
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
Children's Oncology Group
Phase 3 Completed
NCT01288378 2023-12-11
Empirical Versus Preemptive Antifungal Therapy
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT01307579 2021-03-30
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
Children's Oncology Group
Phase 3 Completed
NCT02895529 2019-05-06
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
Xian-Janssen Pharmaceutical Ltd.
Phase 4 Terminated
NCT02856178 2018-02-15
SAFEGUARD
F2G Biotech GmbH
Phase 1/2 Withdrawn
NCT01501708 2016-05-10
Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT00982540 2014-01-29
Dindexval
Universidade Federal do Rio de Janeiro
Phase NA Terminated
NCT00020527 2013-06-19
Caspofungin Acetate in Treating Children With Fever and Neutropenia
National Cancer Institute (NCI)
Phase NA Completed
NCT00008359 2013-01-18
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT00110045 2012-09-24
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00501098 2009-09-22
PROFIL-C
Northern Italy Leukemia Group
Phase 2 Completed